MRK Merck & Company Inc. (new)

65.95
-0.04  -0%
Previous Close 65.99
Open 66.02
Price To book 4.56
Market Cap 179869018723
Shares 2,727,354,340
Volume 6,972,180
Short Ratio 2.74
Av. Daily Volume 7,846,904

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at ESMO 2017 - ORR 57%, PFS 19 months, HR 0.54
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Tentative approval announced July 20, 2017 - subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement.
LUSDUNA Nexvue
Diabetes
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
PDUFA date under priority review Sept. 22, 2017.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 data presented at ASCO 2017. 35% ORR noted in NSCLC arm. UC, RCC, SCCHN data also presented. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
NDA filing due 4Q 2017.
Doravirine (MK-1439)
HIV
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
Phase 3 data due 4Q 2017.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Fully enrolled. Data due in 2019.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 initiated June 2016. Initial data due 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
PDUFA date set for December 2017 - exact date not provided. December 31 entered as latest possible date for calendar entry purposes only.
Ertugliflozin
Type 2 diabetes
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 2b complete.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1

Latest News

  1. Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer
  2. Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
  3. The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
  4. Dow Jones Closes at New High
  5. Major Pharma Short Interest Surges
  6. See what the IHS Markit Score report has to say about Merck & Co Inc.
  7. Bristol-Myers Reports Positive Results from Melanoma Study
  8. Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
  9. Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock
  10. Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  11. Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure
  12. Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma
  13. Inside Merck’s Segment-Wise Performance in 2Q17
  14. Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC
  15. Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval
  16. Behind Merck’s Revenues in 2Q17
  17. Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold
  18. Updated Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress